Protein-protein interactions: Recent progress in the development of selective PDZ inhibitors

Current Chemical Biology

Volumn 3, Issue 2, 2009, Pages 146-158

  Ducki, Sylvie ^a,b   Bennett, Elizabeth ^b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY OF SALFORD   (United Kingdom)

Author keywords

PDZ domain; PDZ inhibitor; Protein protein interaction (PPI)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLUTAMATE RECEPTOR; MONOCLONAL ANTIBODY; NSC 668036; PDZ PROTEIN; PDZ PROTEIN ANTIBODY; PDZ PROTEIN INHIBITOR; PEPTIDOMIMETIC AGENT; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AVIAN INFLUENZA; BINDING AFFINITY; CARCINOGENESIS; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; CYSTIC FIBROSIS; DRUG STRUCTURE; HUMAN; HYDROPHOBICITY; LIGAND BINDING; NONHUMAN; PAIN; PARKINSON DISEASE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SCHIZOPHRENIA;

AVES;

EID: 68449101708     PISSN: 18723136     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231309788166424     Document Type: Review

References (90)

1. Hughes B. 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discovery 2008; 7: 107-9.
2. Ryan DP, Matthews JM. Protein-protein interactions in human disease. Curr Opin Struct Biol 2005; 15(4): 441-6.
3. Fischer EH, Krebs EG. Conversion of Phosphorylase b to Phosphorylase a in muscle extracts. J Biol Chem 1955; 216(1): 121-32.
4. Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303(5665): 1800-5.
5. Kennedy MB. Origin of PDZ (DHR, GLGF) domains. Trends Biochem Sci 1995; 20(9): 350.
6. Cho KO, Hunt CA, Kennedy MB. The rat brain postsynaptic density fraction contains a homolog of the Drosophila discs-large tumor suppressor protein. Neuron 1992; 9(5): 929-42.
7. Woods DF, Bryant PJ. The discs-large tumor suppressor gene of Drosophila encodes a guanylate kinase homolog localized at septate junctions. Cell 1991; 66(3): 451-64.
8. Itoh M, Nagafuchi A, Yonemura S, Kitani-Yasuda T, Tsukita S, Tsukita S. The 220-kD protein colocalizing with cadherins in non-epithelial cells is identical to ZO-1, a tight junction-associated protein in epithelial cells: cDNA cloning and immunoelectron microscopy. J Cell Biol 1993; 121(3): 491-502.
9. Gianni S, Engstrom A, Larsson M, et al. The Kinetics of PDZ Domain-Ligand Interactions and Implications for the Binding Mechanism. J Biol Chem 2005; 280(41): 34805-12.
10. Schultz J, Milpetz F, Bork P, Ponting CP. SMART, a simple modular architecture research tool: Identification of signaling domains. Proc Natl Acad Sci USA 1998; 95(11): 5857-64.
11. Letunic I, Copley RR, Pils B, Pinkert S, Schultz J, Bork P. SMART 5: domains in the context of genomes and networks. Nucleic Acids Res 2006; 34(Database issue).
12. Jelen F, Olesky A, Smietana K, Otlewski J. PDZ Domains - Common players in the cell signaling. Acta Biochim Pol 2003; 50(4): 985-1017.
13. Nourry C, Grant SGN, Borg JP. PDZ domain proteins: plug and play! Sci STKE 2003; 179: RE7.
14. Kurakin A, Swistowski A, Wu SC, Bredesen DE. The PDZ domain as a complex adaptive system. PLoS ONE 2007; 2(9): e953.
15. Sierralta J, Mendoza C. PDZ-containing proteins: alternative splicing as a source of functional diversity. Brain Res Rev 2004; 47(1-3): 105-15.
16. Kay BK, Kehoe JW. PDZ domains and their ligands. Chem Biol 2004;11(4): 423-5.
17. Langnaese K, Richter K, Smalla KH, et al. Splice-isoform specific immunolocalization of neuronal nitric oxide synthase in mouse and rat brain reveals that the PDZ-complex-building nNOS β-finger is largely exposed to antibodies. Dev Neurobiol 2007; 67(4): 422-37.
18. Hillier BJ, Christopherson KS, Prehoda KE, Bredt DS, Lim WA. Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science 1999; 284(5415): 812-5.
19. Fanning AS, Lye MF, Anderson JM, Lavie A. Domain swapping within PDZ2 is responsible for dimerization of ZO proteins. J Biol Chem 2007; 282(52): 37710-6.
20. Shenolikar S, Minkoff CM, Steplock DA, Evangelista C, Liu MZ, Weinman EJ. N-terminal PDZ domain is required for NHERF dimerization. FEBS Lett 2001; 489(2-3): 233-6.
21. Utepbergenov DI, Fanning AS, Anderson JM. Dimerization of the scaffolding protein ZO-1 through the second PDZ domain. J Biol Chem 2006; 281(34): 24671-7.
22. Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H. The protein data bank. Nucleic Acids Res 2000; 28(1): 235-42.
23. Basdevant N, Weinstein H, Ceruso M. Thermodynamic basis for promiscuity and selectivity in protein-protein interactions: PDZ domains, a case study. J Am Chem Soc 2006; 128(39): 12766-77.
24. Wiedemann U, Boisguerin P, Leben R, Leitner D, Krause G, Moelling K. Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding Peptides. J Mol Biol 2004; 343(3): 703-18.
25. Doyle DA, Lee A, Lewis J, Kim E, Sheng M, MacKinnon R. Crystal structures of a complexed and peptide-free membrane protein-binding domain: Molecular basis of peptide recognition by PDZ. Cell 1996; 85(7): 1067-76.
26. Zhou H, Xu Y, Yang Y, Huang A, Wu J, Shi Y. Solution structure of AF-6 PDZ domain and its interaction with the C-terminal peptides from neurexin and Bcr. J Biol Chem 2005; 280(14): 13841-7.
27. Dev KK, Van Der Putten H, Sommer B, Rovelli G. Part I: Parkin-associated proteins and Parkinson's disease. Neuropharmacology 2003; 45(1): 1-13.
28. Fallon L, Moreau F, Croft BG, Labib N, Gu WJ, Fon EA. Parkin and CASK/ LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J Biol Chem 2002; 277(1): 486-91.
29. Songyang Z, Fanning AS, Fu C, et al. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 1997; 275(5296): 73-7.
30. Rousset R, Fabre S, Desbois C, Bantignies F, Jalinot P. The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins. Oncogene 1998;16(5): 643-54.
31. Zhang L, Gao X, Wen J, Ning Y, Chen YG. Dapper 1 antagonizes Wnt signaling by promoting dishevelled degradation. J Biol Chem 2006; 281(13): 8607-12.
32. Birrane G, Chung J, Ladias JAA. Novel Mode of Ligand Recognition by the Erbin PDZ Domain. J Biol Chem 2003; 278(3): 1399-402.
33. Skelton NJ, Koehler MFT, Zobel K, et al. Origins of PDZ domain ligand specificity. Structure determination and mutagenesis of the erbin PDZ domain. J Biol Chem 2003; 278(9): 7645-54.
34. Xia J, Chung HJ, Wihler C, Huganir RL, Linden DJ. Cerebellar long-term depression requires PKC-regulated interactions between GluR2/3 and PDZ domain-containing proteins. Neuron 2000; 28(2): 499-510.
35. Kozlov G, Banville D, Gehring K, Ekiel I. Solution structure of the PDZ2 domain from cytosolic human phosphatase hPTP1E complexed with a peptide reveals contribution of the β2-β3 loop to PDZ domain-ligand interactions. J Mol Biol 2002; 320(4): 813-20.
36. Zhang Y, Dasgupta J, Ma RZ, Banks L, Thomas M, Chen XS. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: Mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J Virol 2007; 81(7): 3618-26.
37. Lee SS, Glaunsinger B, Mantovani F, Banks L, Javier RT. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol 2000; 74(20): 9680-93.
38. Biber J, Gisler SM, Hernando N, Murer H. Protein/protein interactions (PDZ) in proximal tubules. J Membr Biol 2005; 203(3): 111-8.
39. Aceto D, Beers M, Kemphues KJ. Interaction of PAR-6 with CDC-42 is required for maintenance but not establishment of PAR asymmetry in C. elegans. Dev Biol 2006; 299(2): 386-97.
40. Dev KK. Making protein interactions druggable: Targeting PDZ domains. Nat Rev Drug Discovery 2004; 3(12): 1047-56.
41. Madsen KL, Beuming T, Niv MY, Chang CW, Dev KK, Weinstein H, et al. Molecular determinants for the complex binding specificity of the PDZ domain in PICK1. J Biol Chem 2005; 280(21): 20539-48.
42. Pegan S, Tan J, Huang A, Slesinger PA, Riek R, Choe S. NMR studies of interactions between C-terminal tail of Kir2.1 channel and PDZ1,2 domains of PSD95. Biochem 2007; 46(18): 5315-22.
43. Takizawa S, Nagasaka K, Nakagawa S, et al. Human scribble, a novel tumor suppressor identified as a target of high-risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous polyposis coli. Genes Cells 2006; 11(4): 453-64.
44. Meerschaert K, Bruyneel E, De Wever O, Vanloo B, Boucherie C, Bracke M. The tandem PDZ domains of syntenin promote cell invasion. Exp Cell Res 2007; 313(9): 1790-804.
45. Toyofuku T, Akamatsu Y, Zhang H, Kuzuya T, Tada M, Hori M. c-Src regulates the interaction between connexin-43 and ZO-1 in cardiac myocytes. J Biol Chem 2001; 276(3): 1780-8.
46. Pearson WR. Rapid and sensitive sequence comparison with FASTP and FASTA. Methods Enzymol 1990; 183: 63-98.
47. Bezprozvanny I, Maximov A. Classification of PDZ domains. FEBS Letters 2001; 509(3): 457-62.
48. Fan JS, Zhang M. Signaling complex organization by PDZ domain proteins. NeuroSignals 2002; 11(6): 315-21.
49. Tochio H, Hung F, Li M, Bredt DS, Zhang M. Solution structure and backbone dynamics of the second PDZ domain of postsynaptic density-95. J Mol Biol 2000; 295(2): 225-37.
50. Boukerche H, Su Z-z, Emdad L, et al. mda-9/Syntenin: A Positive Regulator of Melanoma Metastasis. Cancer Res 2005; 65(23): 10901-11.
51. Helmke B, Polychronidis M, Benner A, Thome M, Arribas J, Deichmann M. Melanoma metastasis is associated with enhanced expression of the syntenin gene. Oncol Rep 2004; 12(2): 221-8.
52. Tae HK, Lee JJ, Kim E-M, Kim KW, Han DK, Lee JH. Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines. Oncogene 2002; 21(26): 4080-8.
53. Ayllon V, O'Connor R. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene 2007; 26(24): 3451-61.
54. Cardone R, Bellizzi A, Busco G, Weinman E, Dell'Aquila M, Casavola V. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 2007; 18(5): 1768-80.
55. Liu Y, Henry GD, Hegde RS, Baleja JD. Solution structure of the hDlg/ SAP97 PDZ2 domain and its mechanism of interaction with HPV-18 papillomavirus E6 protein. Biochem 2007; 46(38): 10864-74.
56. Hampson L, Li C, Oliver AW, Kitchener HC, Hampson IN. The PDZ protein Tip-1 is a gain of function target of the HPV16 E6 on-coprotein. Int J Oncol 2004; 25(5): 1249-56.
57. Bossard F, Robay A, Toumaniantz G, Dahimene S, Becq F, Merot J. NHE-RF1 protein rescues ΔF508-CFTR function. Am J Physiol Lung Cell Mol Phsyiol 2007; 292(5): L1085-L94.
58. Ji H, Richter W, Namkung W, Kyung H, Kim E, Conti M. Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J Biol Chem 2007; 282(14): 10414-22.
59. Toyooka K, Iritani S, Makifuchi T, Shirakawa O, Kitamura N, Maeda K, et al. Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem 2002; 83(4): 797-806.
60. Dev KK, Henley JM. The schizophrenic faces of PICK1. Trends Pharmacol Sci 2006; 27(11): 574-9.
61. Joch M, Ase A, Chen C, et al. Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol Biol Cell 2007; 18(8): 3105-18.
62. Miller CCJ, McLoughlin DM, Lau KF, Tennant ME, Rogelj B. The X11 proteins, A-beta production and Alzheimer's disease. Trends Neurosci 2006; 29(5): 280-5.
63. Obenauer JC, Denson J, Mehta PK, et al. Large-scale sequence analysis of avian influenza isolates. Science 2006; 311(5767): 1576-80.
64. Zhang B, Tao F, Liaw WJ, Bredt DS, Johns RA, Tao YX. Effect of knock down of spinal cord PSD-93/chapsin0-110 on persistent pain induced by complete Freund's adjuvant and peripheral nerve injury. Pain 2003; 106(1-2): 187-96.
65. Sheng M. Molecular organization of the postsynaptic specialization. Proc Natl Acad Sci USA 2001; 98(13): 7058-61.
66. Folco EJ, Liu G-X, Koren G. Caveolin-3 and SAP97 form a scaf-folding protein complex that regulates the voltage-gated potassium channel Kv1.5. Am J Physiol Heart Circ Physiol 2004; 287(2): H681-90.
67. Tao F, Tao YX, Mao P, Johns RA. Role of postsynaptic density protein-95 in the maintenance of peripheral nerve injury-induced neuropathic pain in rats. Neuroscience 2003; 117(3): 731-9.
68. Stiffler MA, Grantcharova VP, Sevecka M, MacBeath G. Uncovering quantitative protein interaction networks for mouse PDZ domains using protein microarrays. J Am Chem Soc 2006; 128(17): 5913-22.
69. Novak KAP, Fujii N, Guy RK. Investigation of the PDZ domain ligand binding site using chemically modified peptides. Bioorg Med Chem Lett 2002;12(17): 2471-4.
70. Shan J, Shi D-L, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochem 2005; 44(47): 15495-503.
71. Zheng J, Shan J, Wu D; Compositions and methods for the inhibition of dishevelled proteins. Patent WO2006107719. 2006.
72. Piserchio A, Salinas GD, Li T, Marshall J, Spaller MR, Mierke DF. Targeting specific PDZ domains of PSD-95: Structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. Chem Biol 2004; 11(4): 469-73.
73. Udugamasooriya G, Saro D, Spaller MR. Bridged peptide macro-cycles as ligands for PDZ domain proteins. Org Lett 2005; 7(7): 1203-6.
74. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002; 298(5594): 846-50.
75. Cui H, Hayashi A, Sun HS, et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci 2007; 27(37): 9901-15.
76. Tymianski M. Methods and Composition for treating Stroke with Fever. Patent WO2008008348. 2008.
77. Paduch M, Biernat M, Stefanowicz P, Derewenda ZS, Szewczuk Z, Otlewski J. Bivalent peptides as models for multimeric targets of PDZ domains. ChemBioChem 2007; 8(4): 443-52.
78. Klosi E, Saro D, Spaller MR. Bivalent peptides as PDZ domain ligands. Bioorg Med Chem Lett 2007; 17(22): 6147-50.
79. Hammond MC, Bartlett PA. Synthesis of amino acid-derived cyclic acyl amidines for use in β-strand peptidomimetics. J Org Chem 2007; 72(8): 3104-7.
80. Hammond MC, Harris BZ, Lim WA, Bartlett PA. Beta-strand peptidomimetics as potent PDZ domain ligands. Chem Biol 2006; 13(12): 1247-51.
81. Fujii N, Novak KAP, Guy RK, Haresco JJ, Kuntz ID, Stokoe D. A selective irreversible inhibitor targeting a PDZ protein interaction domain. J Am Chem Soc 2003; 125(40): 12074-5.
82. Fujii N, Shelat A, Hall RA, Kiplin Guy R. Design of a selective chemical probe for class I PDZ domains. Bioorg Med Chem Lett 2007; 17(2): 546-8.
83. Fujii N, Haresco JJ, Novak KAP, et al. Rational design of a non-peptide general chemical scaffold for reversible inhibition of PDZ domain interactions. Bioorg Med Chem Lett 2007; 17(2): 549-52.
84. Fujii N, You L, Xu Z, et al. An antagonist of dishevelled protein-protein interaction suppresses β-catenin-dependent tumor cell growth. Cancer Res 2007; 67(2): 573-9.
85. Guy RK, Fujii N, You L, Jablons DM. Preparation of aromatic heterocyclic compounds as PDZ domain inhibitors for treatment of cancer. Patent WO2006007542 2006.
86. Mayasundari A, Ferreira AM, He L, Mahindroo N, Bashford D, Fujii N. Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains. Bioorg Med Chem Lett 2008; 18(3): 942-5.
87. Guy RK, Kuntz ID, Haresco JJ, et al. Small-Molecule inhibition of a PDZ-domain interaction. Patent WO20080021082. 2008.
88. Joshi M, Oschkinat H, Schade M, Vargas C; PDZ-Domain Modulators. Patent WO2006119736. 2006.
89. Joshi M, Vargas C, Boisguerin P, et al. Discovery of low-molecular-weight ligands for the AF6 PDZ domain. Angew Chem Int Ed 2006; 45(23): 3790-5.
90. Belmares MP, Lu PS, Mendoza KA. Small molecule inhibitors of PDZ interactions. Patent WO2007079406. 2007.